Bosentan as an endothelin-1 receptor antagonist is however suggested as a potential therapeutic option for CDH-PH by following research showing that dysregulation of ET-A receptors and elevated ET-1 may contribute to CDH-PH. Here, EDNRA is linked to congenital diaphragmatic hernia.